Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI

Study Overview
=================
Brief Summary
-----------------
Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.

Official Title
-----------------
Evaluation of the Tolerance of Anti-MRSA Betalactamines (Ceftaroline / Ceftobiprole) in the Management of BJI / PJI: a Retrospective Study in a Reference Center

Conditions
-----------------
Antibiotic Reaction, Bone and Joint Infection

Intervention / Treatment
-----------------
* Other: Description of use of ceftaroline and ceftobiprole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having had a PJI or BJI treated whith ceftaroline and/or ceftobiprole Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Description of use of ceftaroline and ceftobiprole<br>description of patients and their PJI/BJI,conditions of use, adverse event | Other: Description of use of ceftaroline and ceftobiprole<br>* Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of use of ceftaroline and ceftobiprole : patients | type of patients: age, CMI | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| Evaluation of use of ceftaroline: dosage | dosage,duration | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| Evaluation of use of ceftaroline : PJI/BJI | description of the PJI/BJI treated by ceftaroline : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| Evaluation of use of ceftobiprole: dosage | dosage, duration | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| Evaluation of use of ceftobiprole: PJI/BJI | description of the PJI/BJI treated by ceftobiprole : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| rate of failure under ceftaroline | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 
| rate of failure under ceftobiprole | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment-related adverse events | description of adverse event under ceftaroline and/or ceftobiprole as assessed by CTCAE v4.0 | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bone and joint infection, prosthesis joint infection, adverse event, ceftaroline, ceftobiprole